Amyloidosis relapsing after autologous stem cell transplantation treated with bortezomib: normalization of detectable serum-free light chains and reversal of tissue damage with improved suitability for transplant

被引：6
作者：
Brunvand, Mark W. [1 ]
Bitter, Mitchell [2 ]
机构：
[1] Rocky Mt Blood & Marrow Transplant Program, Denver, CO 80218 USA
[2] Unipath, Denver, CO USA
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷 / 03期
关键词：
SYSTEMIC AL AMYLOIDOSIS; CHEMOTHERAPY; SURVIVAL;
D O I：
10.3324/haematol.2009.013102
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：519 / 521
页数：3
相关论文
共 11 条
  • [1] Comenzo RL, 2007, CONTRIB NEPHROL, V153, P195
  • [2] Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study
    Dispenzieri, A
    Kyle, RA
    Lacy, MQ
    Therneau, TM
    Larson, DR
    Plevak, MF
    Rajkumar, SV
    Fonseca, R
    Greipp, PR
    Witzig, TE
    Lust, JA
    Zeldenrust, SR
    Snow, DS
    Hayman, SR
    Litzow, MR
    Gastineau, DA
    Tefferi, A
    Inwards, DJ
    Micallef, IN
    Ansell, SM
    Porrata, LF
    Elliott, MA
    Gertz, MA
    [J]. BLOOD, 2004, 103 (10) : 3960 - 3963
  • [3] Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report
    Gertz, MA
    Lacy, MQ
    Dispenzieri, A
    [J]. BONE MARROW TRANSPLANTATION, 2000, 25 (05) : 465 - 470
  • [4] Transplantation for amyloidosis
    Gertz, Morie A.
    Lacy, Martha Q.
    Dispenzieri, Angela
    Hayman, Suzanne R.
    Kumar, Shaji
    [J]. CURRENT OPINION IN ONCOLOGY, 2007, 19 (02) : 136 - 141
  • [5] Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy
    Lachmann, HJ
    Gallimore, R
    Gillmore, JD
    Carr-Smith, HD
    Bradwell, AR
    Pepys, MB
    Hawkins, PN
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2003, 122 (01) : 78 - 84
  • [6] Molecular mechanisms of amyloidosis
    Merlini, G
    Bellotti, V
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (06) : 583 - 596
  • [7] Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients
    Moreau, P
    Leblond, V
    Bourquelot, P
    Facon, T
    Huynh, A
    Caillot, D
    Hermine, O
    Attal, M
    Hamidou, M
    Nedellec, G
    Ferrant, A
    Audhuy, B
    Bataille, R
    Milpied, N
    Harousseau, JL
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1998, 101 (04) : 766 - 769
  • [8] Bortezomib in the front-line treatment of multiple myeloma
    Richardson, Paul G.
    Mitsiades, Constantine
    Schlossman, Robert
    Ghobrial, Irene
    Hideshima, Teru
    Munshi, Nikhil
    Anderson, Kenneth C.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (07) : 1053 - 1072
  • [9] Long-term outcome-of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation
    Sanchorawala, Vaishali
    Skinner, Martha
    Quillen, Karen
    Finn, Kathleen T.
    Doros, Gheorghe
    Seldin, David C.
    [J]. BLOOD, 2007, 110 (10) : 3561 - 3563
  • [10] Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease
    Wechalekar, Ashutosh D.
    Lachmann, Helen J.
    Offer, Mark
    Hawkins, Philip N.
    Gillmore, Julian D.
    [J]. HAEMATOLOGICA, 2008, 93 (02) : 295 - 298
12